Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China · Delayed Price · Currency is CNY 56.80
+2.36 (4.34%)
May 8, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 886.35 | 899.45 | 862.37 | 752.26 | 3,387 | 1,873 |
Other Revenue | 5.9 | 5.9 | 4.22 | 2.44 | 1.47 | 0.86 |
| 892.24 | 905.34 | 866.58 | 754.7 | 3,389 | 1,873 | |
Revenue Growth (YoY) | 1.95% | 4.47% | 14.82% | -77.73% | 80.88% | 64.98% |
Cost of Revenue | 447.84 | 448.35 | 392.82 | 380.66 | 1,563 | 843.87 |
Gross Profit | 444.4 | 456.99 | 473.77 | 374.04 | 1,826 | 1,030 |
Selling, General & Admin | 166.48 | 159.06 | 120.23 | 135.87 | 228.4 | 82.48 |
Research & Development | 116.91 | 109.32 | 95.82 | 121.17 | 207.3 | 95.46 |
Other Operating Expenses | 12.4 | 9.29 | 9.24 | 6.66 | 27.55 | 9.87 |
Operating Expenses | 297.78 | 280.85 | 233.17 | 275.02 | 471.08 | 191.89 |
Operating Income | 146.62 | 176.14 | 240.6 | 99.01 | 1,354 | 837.67 |
Interest Expense | -0.43 | -0.28 | -0.42 | -1.46 | -2.17 | -0.67 |
Interest & Investment Income | 28.24 | 25.83 | 45.66 | 54.2 | 67 | 44.86 |
Currency Exchange Gain (Loss) | -12.95 | -12.95 | 5.85 | 15.85 | 31.74 | -18.28 |
Other Non Operating Income (Expenses) | -20.96 | -1.83 | 0.81 | -1.33 | 0.73 | -3.95 |
EBT Excluding Unusual Items | 140.53 | 186.92 | 292.51 | 166.28 | 1,452 | 859.63 |
Impairment of Goodwill | - | - | - | - | -14.01 | - |
Gain (Loss) on Sale of Investments | 44.13 | 40.61 | 35.55 | 32.67 | -15.22 | 21.33 |
Gain (Loss) on Sale of Assets | 0.66 | 0.6 | 1.22 | -0.66 | 0.52 | -0.08 |
Asset Writedown | 0.05 | - | - | -0.28 | -60.7 | - |
Other Unusual Items | 23.05 | 23.05 | 18.44 | -0.57 | 19.11 | 14.65 |
Pretax Income | 208.42 | 251.18 | 347.71 | 197.44 | 1,381 | 895.53 |
Income Tax Expense | 30.39 | 31.1 | 44.8 | 17.16 | 195.99 | 129.84 |
Earnings From Continuing Operations | 178.02 | 220.07 | 302.91 | 180.28 | 1,185 | 765.69 |
Minority Interest in Earnings | 0.35 | 0.12 | -0.44 | 0.3 | -0.54 | - |
Net Income | 178.37 | 220.19 | 302.47 | 180.58 | 1,185 | 765.69 |
Net Income to Common | 178.37 | 220.19 | 302.47 | 180.58 | 1,185 | 765.69 |
Net Income Growth | -44.07% | -27.20% | 67.50% | -84.76% | 54.75% | 12.73% |
Shares Outstanding (Basic) | 80 | 79 | 79 | 79 | 79 | 75 |
Shares Outstanding (Diluted) | 80 | 79 | 79 | 79 | 79 | 75 |
Shares Change (YoY) | 0.60% | 0.03% | -0.02% | -0.07% | 5.96% | 25.16% |
EPS (Basic) | 2.24 | 2.78 | 3.82 | 2.28 | 14.95 | 10.24 |
EPS (Diluted) | 2.24 | 2.78 | 3.82 | 2.28 | 14.95 | 10.24 |
EPS Growth | -44.40% | -27.22% | 67.54% | -84.75% | 46.05% | -9.93% |
Free Cash Flow | 5.84 | -12.5 | 108.87 | -508.73 | 1,090 | 783.75 |
Free Cash Flow Per Share | 0.07 | -0.16 | 1.38 | -6.42 | 13.76 | 10.48 |
Dividend Per Share | 2.000 | 2.000 | 3.000 | 1.500 | 6.757 | 2.703 |
Dividend Growth | -33.33% | -33.33% | 100.00% | -77.80% | 150.00% | 99.99% |
Gross Margin | 49.81% | 50.48% | 54.67% | 49.56% | 53.87% | 54.96% |
Operating Margin | 16.43% | 19.46% | 27.76% | 13.12% | 39.97% | 44.71% |
Profit Margin | 19.99% | 24.32% | 34.90% | 23.93% | 34.97% | 40.87% |
Free Cash Flow Margin | 0.65% | -1.38% | 12.56% | -67.41% | 32.18% | 41.84% |
EBITDA | 189.58 | 215.68 | 266.44 | 120.18 | 1,378 | 846.45 |
EBITDA Margin | 21.25% | 23.82% | 30.75% | 15.92% | 40.65% | 45.18% |
D&A For EBITDA | 42.96 | 39.53 | 25.84 | 21.17 | 23.11 | 8.78 |
EBIT | 146.62 | 176.14 | 240.6 | 99.01 | 1,354 | 837.67 |
EBIT Margin | 16.43% | 19.46% | 27.76% | 13.12% | 39.97% | 44.71% |
Effective Tax Rate | 14.58% | 12.38% | 12.88% | 8.69% | 14.19% | 14.50% |
Revenue as Reported | 892.24 | 905.34 | 866.58 | 754.7 | 3,389 | 1,873 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.